Device Trial Radar · NCT04215640
Radiofrequency Ablation of Paroxysmal Supraventricular Tachycardia Using a Novel Catheter Equipped With Mini Electrodes
Last checked: Nov 19, 2026Latest source record: Nov 2, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
136
Actual
Start
Jan 13, 2020
Primary completion
Nov 1, 2021
Study completion Nov 1, 2021
Sponsor
- Lead sponsor
- Yong Seog OhAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jan 2, 2020
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- FDA-regulated device
- No
- Who can join
- All sexes, from 15 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Paroxysmal supraventricular tachycardia is treated with radiofrequency ablation recently. This procedure is performed by ablating slow pathway or accessory pathway using radiofrequency ablation catheter. Recently developed mirofidelity (MIFI) catheter has mini-electrodes that can record local eletrogram with higher resolution. We aimed to investigate the efficacy of MIFI catheter in the ablation of paroxysmal supraventricular tachycardia compared to conventional radiofrequency ablation catheter. Enrolled patients undergo conventional electrophysiologic study. Patients with sustained supraventricular tachycardia during the study are randomized to either study group or control group. Radiofrequency ablation is performed using MIFI catheter in the study group, and conventional catheter (Blazer II) in the control group. The study endpoints are recorded immediately after ablation and there is no additional follow up or management after procedure.
Conditions
- Paroxysmal Supraventricular Tachycardia
Interventions
Microfidelity (MIFI) catheterDevice
Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Microfidelity (MIFI) catheter equipped with mini-electrodes will be used for ablation in the MIFI group.
Conventional ablation catheterDevice
Patients are randomized into the MIFI group and control group. Radiofrequency ablation will target slow pathway for AVNRT or accessory pathway for AVRT. Blazer II radiofrequency ablation catheter will be used for ablation in the control group.
Primary outcomes
What the sponsor says the trial is designed to measure.
- RF time (seconds) to successful ablationTime frame: At the end of radiofrequency ablation procedure
- RF application numberTime frame: At the end of radiofrequency ablation procedure
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Seoul St Mary's Hospital
Seoul, Seo Ch-gu, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.